Spiral computed tomography of the liver: contrast agent pharmacokinetics and the potential for improved hepatic enhancement.
We conducted a prospective study of 131 patients to evaluate the contrast agent dose-response relationship for liver spiral computed tomography (CT) and to test the hypothesis that spiral CT scanning provides greater enhancement than does dynamic CT scanning. Patients were assigned to one of two control groups (dynamic CT) or to one of five experimental groups (spiral CT). Dynamic CT patients received 150 ml and spiral CT patients received either 75, 100, or 150 ml of diatrizoate meglumine. All groups had a monophasic injection rate of 2.5 ml/sec. Hepatic enhancement was compared among experimental and control groups. In the experimental groups, there was a linear dose-response relationship (p < .0001) among the enhancements achieved for the three dosages. The enhancement of the last slice of liver for the spiral CT versus dynamic CT groups receiving 150 ml was significantly greater (p = .002). Peak, first liver slice, and average liver enhancement values were higher with spiral CT scanning, but the difference was not statistically significant (power > .55). Using uniphasic injection rates and identical doses of contrast agent, spiral CT scanning has the advantage of improved enhancement of the last part of the liver to be imaged.